This is a summary of the European Public Assessment Report (EPAR) for Vantavo. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vantavo.
Therapeutic Indication
Treatment of postmenopausal osteoporosis in patients at risk of vitamin\-D insufficiency. Vantavo reduces the risk of vertebral and hip fractures. Treatment of postmenopausal osteoporosis in patients who are not receiving vitamin\-D supplementation and are at risk of vitamin\-D insufficiency. Vantavo reduces the risk of vertebral and hip fractures.
Therapeutic Area (MeSH)
ATC Code
M05BB03
ATC Item
N/A
Pharmacotherapeutic Group
Drugs for treatment of bone diseases
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| alendronic acid | N/A | alendronic acid |
| colecalciferol | N/A | colecalciferol |
EMA Name
Vantavo (previously Alendronate sodium and colecalciferol, MSD)
Medicine Name
Vantavo (previously Alendronate sodium and colecalciferol, MSD)
Aliases
N/ANo risk management plan link.
